UPDATE: Barclays Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight; Three Shots on Goal
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $67.36 -1.71%
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - August 24, 2012 12:23 PM EDT)
Barclays initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with an Overweight. PT $46.00.
Analyst, Ying Huang, said, "We expect near-term inflection points on BMRN with three shots on goal (PEG-PAL, GALNS, and BMN-701). Although expectations have been reflected in stock price to some extent (at least for GALNS), we believe positive outcomes provide significant upside potential."
In Sum, Huang sees GALNS likely to succeed; PEG-PAL moving to final phase of testing; and BMN-701 represents additional upside.
For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $37.94 yesterday.
Barclays initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with an Overweight. PT $46.00.
Analyst, Ying Huang, said, "We expect near-term inflection points on BMRN with three shots on goal (PEG-PAL, GALNS, and BMN-701). Although expectations have been reflected in stock price to some extent (at least for GALNS), we believe positive outcomes provide significant upside potential."
In Sum, Huang sees GALNS likely to succeed; PEG-PAL moving to final phase of testing; and BMN-701 represents additional upside.
For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $37.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
- JPMorgan Resumes SanDisk (SNDK) at Overweight
- Barclays: US stocks sell off despite historic earnings beats
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
